[go: up one dir, main page]

PE20050251A1 - Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc - Google Patents

Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc

Info

Publication number
PE20050251A1
PE20050251A1 PE2004000685A PE2004000685A PE20050251A1 PE 20050251 A1 PE20050251 A1 PE 20050251A1 PE 2004000685 A PE2004000685 A PE 2004000685A PE 2004000685 A PE2004000685 A PE 2004000685A PE 20050251 A1 PE20050251 A1 PE 20050251A1
Authority
PE
Peru
Prior art keywords
aliphatic
aryl
ns4a
protease
serine protease
Prior art date
Application number
PE2004000685A
Other languages
English (en)
Inventor
Robert B Perni
Shawn D Britt
Kevin M Cottrell
Janos Pitlik
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20050251A1 publication Critical patent/PE20050251A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE X Y X' SON AMBOS FLUORINOS O CADA UNO ES C(H), N, NH, ENTRE OTROS; Y E Y' SON CADA UNO H, ARILO C6-C10, HETEROARILO C5-C10, ENTRE OTROS; R1 Y R3 SON CADA UNO CICLOALQUENILO, C1-C12-ALIFATICO, C6-C10-ARILO-C1-C12-ALIFATICO, ENTRE OTROS; R2, R4 Y R7 SON CADA UNO H, C1-C12-ALIFATICO, C6-C10-ARILO-C1-C12-ALIFATICO, ENTRE OTROS; R5 Y R5' SON CADA UNO H, C1-C12-ALIFATICO, ENTRE OTROS; V ES O, ENLACE DE VALENCIA; T ES C1-C12-ALIFATICO, C6-C10-ARILO, ENTRE OTROS; W ES (A), (B), ENTRE OTROS; DONDE R6 ES H, C6-C10-ARILO, C1-C12-ALIFATICO; ENTRE OTROS. TAMBIEN REFERIDA A LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 3-ACETIL-4,5-DIMETIL-ACIDO CARBOXILICO PIRROL; 2-(2-{2-CICLOHEXIL-2-[(PIRAZINO-2-CARBONIL)-AMINO]-ACETILAMINO}-3,3-DIMETIL-BUTIRIL)-6.10-DITIA-2-AZAESPIRO[4,5]DECANO-3-ACIDO CARBOXILICO(1-CICLOPROPILAMINOOXALIL-BUTIL)-AMIDA; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE PROTEASA DE SERINA, DEL VIRUS DE HEPATITIS C DE LA PROTEASA NS3-NS4A, ENTRE OTRAS
PE2004000685A 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc PE20050251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18

Publications (1)

Publication Number Publication Date
PE20050251A1 true PE20050251A1 (es) 2005-04-13

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000685A PE20050251A1 (es) 2003-07-18 2004-07-16 Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc

Country Status (18)

Country Link
US (2) US7109172B2 (es)
EP (3) EP1646642A2 (es)
JP (2) JP4745230B2 (es)
KR (2) KR20120013450A (es)
CN (3) CN102020700A (es)
AR (1) AR045916A1 (es)
AU (2) AU2004257288A1 (es)
BR (1) BRPI0412761A (es)
CA (1) CA2532664A1 (es)
IL (2) IL173180A0 (es)
NO (1) NO20060706L (es)
NZ (1) NZ544789A (es)
PE (1) PE20050251A1 (es)
RU (1) RU2412198C2 (es)
TW (1) TW200523270A (es)
UY (1) UY28423A1 (es)
WO (1) WO2005007681A2 (es)
ZA (1) ZA200601420B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) * 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
PT1268519E (pt) * 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
SG159385A1 (en) * 2002-04-11 2010-03-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7109172B2 (en) * 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
EP1664091A1 (en) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP2361925A1 (en) * 2003-10-10 2011-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
RU2006118359A (ru) * 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
WO2005077969A2 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SG161315A1 (en) 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
US7772178B2 (en) * 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
CA2610167A1 (en) 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
EP2402331A1 (en) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
CN101489557B (zh) 2006-02-27 2013-12-18 弗特克斯药品有限公司 包含vx-950的共晶体和包含所述共晶体的药物组合物
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
BRPI0710878A2 (pt) * 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
BRPI0714343A2 (pt) 2006-07-13 2013-03-19 Achillion Pharmaceuticals Inc peptÍdeos de 4-amino-4-oxobutanoil como inibidores de replicaÇço viral
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
WO2008057995A2 (en) * 2006-11-02 2008-05-15 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
BRPI0718915A2 (pt) 2006-11-15 2013-12-03 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
PT2144604E (pt) * 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2185546B1 (en) 2007-08-30 2011-10-26 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
SI2364309T1 (sl) 2008-12-10 2015-03-31 Achillion Pharmaceuticals, Inc. Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
AU2009352688B2 (en) 2009-09-15 2014-04-17 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
AU2010336355A1 (en) 2009-12-24 2012-07-05 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
WO2011119860A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
CA2808291A1 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AR087346A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Formulaciones de compuestos de tiofeno
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014152928A2 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
EP3212290A4 (en) * 2014-10-27 2019-01-23 Inhibrx LP SERPINFUSION POLYPEPTIDES AND METHOD OF USE THEREOF
CN109476637B (zh) 2016-06-21 2022-02-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
CA2282398A1 (en) 1997-03-14 1998-09-17 Steven M. Ronkin Inhibitors of impdh enzyme
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
TR200103428T2 (tr) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzim inhibitörleri.
PT1268519E (pt) 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
NZ523782A (en) * 2000-07-21 2005-10-28 Dendreon Corp Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE60217114T2 (de) * 2001-07-11 2007-10-25 Vertex Pharmaceuticals Inc., Cambridge Verbrückte bizyklische serinproteaseinhibitoren
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
SG159385A1 (en) * 2002-04-11 2010-03-30 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
CA2495843A1 (en) 2002-09-04 2004-03-18 Mark Straubhaar Optoelectronic device for the treatment of muscle or joint pain
US20050090450A1 (en) * 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PE20050374A1 (es) * 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
EP1664091A1 (en) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP2361925A1 (en) * 2003-10-10 2011-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005077969A2 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
JP2010519329A (ja) 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤

Also Published As

Publication number Publication date
KR20120013450A (ko) 2012-02-14
CN1852920A (zh) 2006-10-25
EP2341065A3 (en) 2012-06-20
IL218698A0 (en) 2012-05-31
NZ544789A (en) 2010-01-29
UY28423A1 (es) 2005-02-28
RU2412198C2 (ru) 2011-02-20
RU2006105002A (ru) 2006-08-27
JP2011116784A (ja) 2011-06-16
EP2368900A3 (en) 2012-07-04
WO2005007681A3 (en) 2005-06-02
WO2005007681A2 (en) 2005-01-27
KR20060052836A (ko) 2006-05-19
IL173180A0 (en) 2006-06-11
CN102020700A (zh) 2011-04-20
CN1852920B (zh) 2010-12-15
EP2368900A2 (en) 2011-09-28
EP2341065A2 (en) 2011-07-06
AU2004257288A2 (en) 2008-06-26
EP1646642A2 (en) 2006-04-19
US20050107304A1 (en) 2005-05-19
US8691758B2 (en) 2014-04-08
CN101724022A (zh) 2010-06-09
CA2532664A1 (en) 2005-01-27
JP4745230B2 (ja) 2011-08-10
AU2010257200B2 (en) 2011-10-20
US20060211629A1 (en) 2006-09-21
AU2010257200A1 (en) 2011-01-13
BRPI0412761A (pt) 2006-09-26
ZA200601420B (en) 2007-06-27
AR045916A1 (es) 2005-11-16
AU2004257288A1 (en) 2005-01-27
JP2008500265A (ja) 2008-01-10
HK1098164A1 (en) 2007-07-13
US7109172B2 (en) 2006-09-19
TW200523270A (en) 2005-07-16
NO20060706L (no) 2006-02-14

Similar Documents

Publication Publication Date Title
PE20050251A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc
PE20050374A1 (es) Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CY1107200T1 (el) Ενωσεις αναστολης της ηπατιτιδας c
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
BRPI0407827A (pt) compostos de aminoeteroarila como inibidores de proteìna cinase
PE20030857A1 (es) Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
MA30198B1 (fr) Inhibiteurs de la protease ns3 du vhc
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
MA29757B1 (fr) Peptides macrocycliques en tant qu'inhibiteurs de la protease ns3 du vhc
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
ATE466856T1 (de) Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
EA200400023A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтическое использование и материалы для их синтеза
EA200400022A1 (ru) Соединения и способы лечения или предупреждения инфекций flavivirus
NO20062267L (no) Hepatitt C virus inhibitorer
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
EA199800661A1 (ru) Ингибиторы аспартильных протеаз
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
PE20081312A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
TH124102A (th) สารยับยั้งเปปไทโดไมเมทิคโปรทีเอส

Legal Events

Date Code Title Description
FC Refusal